drugset / Trial / NCT04521452

Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

NCT04521452

Phase 4 Unknown 218 enrolled Asan Medical Center REDNVIA Co., Ltd. · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess an inhibitory effect of Evogliptin on the progression of mild-to-moderate aortic stenosis in patients with T2DM and calcific aortic stenosis.

Timeline

Start
2020-09
Primary completion
2024-09
Completion
2024-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Evogliptin Small molecule 5 mg

Indications

No indication recorded.